Multi-Modal MRI to Assess Alzheimer's Disease Prevention in an APOE4 MouseModel
Description: Narrative The proposed research is relevant to public health because we will use multi-modal MRI as surrogate markers to assess efficacy of Rapamycin for restoring brain vascular, metabolic, and structural functions in mice that carry APOE4 genes, the strongest genetic risk factor for Alzheimer's disease (AD). Because MRI methods are readily able to be used in humans and Rapamycin is FDA-approved, the findings from the study will provide valuable information, and may pave a way, for future Rapamycin clinical trials to prevent AD for pre- symptomatic APOE4 carriers.
Funder: National Institute on Aging
Funding type: research
Funder scheme: R01
Start date: 2017-07-01
End date: 2025-04-30
Investigator: AI-LING LIN (lead)
Institutions: University of Missouri, UNIVERSITY OF MISSOURI-COLUMBIA
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Funded outputs count: 31
Funder award ID: R01AG054459
OpenAlex ID: G6936018654
